A role for very low-dose recombinant activated factor VII in refractory bleeding after cardiac surgery: Lessons from an observational study

Journal of Thoracic and Cardiovascular Surgery

Volumn 156, Issue 4, 2018, Pages 1564-1573.e8

  Hoffmann, Till ^a   Assmann, Alexander ^b,e   Dierksen, Angelika ^b   Roussel, Elisabeth ^a   Ullrich, Sebastian ^c   Lichtenberg, Artur ^b   Albert, Alexander ^b   Sixt, Stephan ^d  

^a Transfusion Medicine and Clinical Haemostaseology   (United States)

^b Department of Cardiovascular Surgery ^*  (United States)

^c Life Science Center   (Germany)

^d Department of Orthopedic Surgery   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

bleeding; cardiac surgery; patient blood management; recombinant activated factor VII; safety

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT PROTEIN;

ADULT; AGED; AORTIC SURGERY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART SURGERY; HEMOSTASIS; HOSPITAL MORTALITY; HOSPITAL READMISSION; HUMAN; IMPLANTATION; KIDNEY FAILURE; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE SURGERY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; REFRACTORY BLEEDING; THROMBOEMBOLISM; TREATMENT DURATION; ADVERSE EVENT; MIDDLE AGED; PROCEDURES;

AGED; CARDIAC SURGICAL PROCEDURES; COAGULANTS; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 85047917865     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2018.03.167     Document Type: Article

References (39)

1. Goodnough, L.T., Levy, J.H., Off-label use of recombinant human factor VIIa. Ann Thorac Surg 98 (2014), 393–395.
2. Simpson, E., Lin, Y., Stanworth, S., Birchall, J., Doree, C., Hyde, C., Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane database Syst Rev, 2012, CD005011.
3. Kozek-Langenecker, S.A., Afshari, A., Albaladejo, P., Santullano, C.A., De Robertis, E., Filipescu, D.C., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 30 (2013), 270–382.
4. American Society of Anesthesiologists Task Force on Perioperative Blood M. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists task force on perioperative blood management*. Anesthesiology 122 (2015), 241–275.
5. Vuylsteke, A., Pagel, C., Gerrard, C., Reddy, B., Nashef, S., Aldam, P., et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg 39 (2011), 924–930.
6. Hacquard, M., Durand, M., Lecompte, T., Boini, S., Briancon, S., Carteaux, J.P., Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg 40 (2011), 1320–1327.
7. Alfirevic, A., Duncan, A., You, J., Lober, C., Soltesz, E., Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 98 (2014), 618–624.
8. Gill, R., Herbertson, M., Vuylsteke, A., Olsen, P.S., von Heymann, C., Mythen, M., et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120 (2009), 21–27.
9. Karkouti, K., Beattie, W.S., Arellano, R., Aye, T., Bussieres, J.S., Callum, J.L., et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 118 (2008), 331–338.
10. Levi, M., Levy, J.H., Andersen, H.F., Truloff, D., Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 363 (2010), 1791–1800.
11. Mitra, B., Phillips, L., Cameron, P.A., Billah, B., Reid, C., The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 38 (2010), 671–677.
12. Ponschab, M., Landoni, G., Biondi-Zoccai, G., Bignami, E., Frati, E., Nicolotti, D., et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 25 (2011), 804–810.
13. Brase, J., Finger, B., He, J., Wirtz, K., Stun, L., McMillen, R., et al. Analysis of outcomes using low-dose and early administration of recombinant activated factor VII in cardiac surgery. Ann Thorac Surg 102 (2016), 35–40.
14. Safani, M., Drachenberg, M.R., Ferro, E.T., Hill, S.E., Thomas, G.S., Bethencourt, D.M., Low-dose recombinant activated factor VII (rF-VIIa) for excess hemorrhage after cardiac operation. Ann Thorac Surg, 99, 2015, 1870.
15. van de Garde, E.M., Bras, L.J., Heijmen, R.H., Knibbe, C.A., van Dongen, E.P., Wiltink, E.H., et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth 20 (2006), 573–575.
16. Gelsomino, S., Lorusso, R., Romagnoli, S., Bevilacqua, S., De Cicco, G., Bille, G., et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. Eur J cardiothorac Surg 33 (2008), 64–71.
17. Romagnoli, S., Bevilacqua, S., Gelsomino, S., Pradella, S., Ghilli, L., Rostagno, C., et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 102 (2006), 1320–1326.
18. Yank, V., Tuohy, C.V., Logan, A.C., Bravata, D.M., Staudenmayer, K., Eisenhut, R., et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154 (2011), 529–540.
19. Zatta, A., McQuilten, Z., Kandane-Rathnayake, R., Isbister, J., Dunkley, S., McNeil, J., et al. The Australian and New Zealand haemostasis registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus 13 (2015), 86–99.
20. Andersen, N.D., Bhattacharya, S.D., Williams, J.B., Fosbol, E.L., Lockhart, E.L., Patel, M.B., et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 93 (2012), 1921–1928 discussion 1928-9.
21. Yan, W., Xuan, C., Ma, G., Zhang, L., Dong, N., Wang, Z., et al. Combination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations. J Cardiothorac Surg, 9, 2014, 156.
22. Chapman, A.J., Blount, A.L., Davis, A.T., Hooker, R.L., Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg 40 (2011), 1314–1318 discussion 1318-9.
23. Karkouti, K., Beattie, W.S., Wijeysundera, D.N., Yau, T.M., McCluskey, S.A., Ghannam, M., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45 (2005), 26–34.
24. Raivio, P., Suojaranta-Ylinen, R., Kuitunen, A.H., Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 80 (2005), 66–71.
25. Anselmi, A., Guinet, P., Ruggieri, V.G., Aymami, M., Lelong, B., Granry, S., et al. Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 49 (2016), 78–84.
26. Karkouti, K., Arellano, R., Aye, T., Dupuis, J.Y., Kent, B., Lee, T.W., et al. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). Can J Anaesth 61 (2014), 727–735.
27. Pradeep, A., Rajagopalam, S., Kolli, H.K., Patel, N., Venuto, R., Lohr, J., et al. High volumes of intravenous fluid during cardiac surgery are associated with increased mortality. HSR Proc Intensive Care Cardiovasc Anesth 2 (2010), 287–296.
28. Karkouti, K., Callum, J., Wijeysundera, D.N., Rao, V., Crowther, M., Grocott, H.P., et al. Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial. Circulation 134 (2016), 1152–1162.
29. Weber, C.F., Gorlinger, K., Meininger, D., Herrmann, E., Bingold, T., Moritz, A., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 117 (2012), 531–547.
30. Wikkelso, A., Wetterslev, J., Moller, A.M., Afshari, A., Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane database Syst Rev, 2016, CD007871.
31. Lisman, T., de Groot, P.G., The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Rev 29 (2015), 223–229.
32. Omar, H.R., Enten, G., Karlnoski, R., Ching, Y.H., Mangar, D., Camporesi, E.M., Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. Drugs R D 15 (2015), 187–194.
33. Diprose, P., Herbertson, M.J., O'Shaughnessy, D., Gill, R.S., Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95 (2005), 596–602.
34. Tritapepe, L., De Santis, V., Vitale, D., Nencini, C., Pellegrini, F., Landoni, G., et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Crit Care Med 35 (2007), 1685–1690.
35. Bishop, C.V., Renwick, W.E., Hogan, C., Haeusler, M., Tuckfield, A., Tatoulis, J., Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 81 (2006), 875–879.
36. Hogue, C.W. Jr., Murphy, S.F., Schechtman, K.B., Davila-Roman, V.G., Risk factors for early or delayed stroke after cardiac surgery. Circulation 100 (1999), 642–647.
37. Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Glob Heart 7 (2012), 275–295.
38. Hansen, B.B., Bowers, J., Covariate balance in simple, stratified and clustered comparative studies. Stat Sci 23 (2008), 219–236.
39. Iacus, S.M., King, G., Porro, G., Multivariate matching methods that are monotonic imbalance bounding. J Am Stat Assoc 106 (2011), 345–361.